Alector, Inc. Profile Avatar - Palmy Investing

Alector, Inc.

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment…

Biotechnology
US, South San Francisco [HQ]
Revenue Breakdowns

Segment Analysis Beta

The financial segments are sourced from the SEC' 10-K statement.

Revenue By Top Segments

Alector, Inc. can't present it's sankey chart.

Historical Revenue By Segment

Last 3Y, in million USD

Alector, Inc. can't present revenue by segment

End of ALEC's Analysis
CIK: 1653087 CUSIP: 014442107 ISIN: US0144421072 LEI: - UEI: -
Secondary Listings
ALEC has no secondary listings inside our databases.